Información de ANI Pharmaceuticals Inc, dividendo de ANI Pharmaceuticals Inc, actividades de los accionistas y más

Más Datos de ANI Pharmaceuticals Inc Compañía

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

Información de ANI Pharmaceuticals Inc



Símbolo de cotizaciónANIP

Nombre de la empresaANI Pharmaceuticals Inc

Fecha de salida a bolsaMay 04, 2000

Director ejecutivoLalwani (Nikhil Suresh)

Número de empleados897

Tipo de seguridadOrdinary Share

Fin del año fiscalMay 04

Dirección210 Main Street West

CiudadBAUDETTE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal56623

Teléfono12186343500

Sitio Webhttps://www.anipharmaceuticals.com/

Símbolo de cotizaciónANIP

Fecha de salida a bolsaMay 04, 2000

Director ejecutivoLalwani (Nikhil Suresh)

Ejecutivos de ANI Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

411.22K

-56960.00%

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

310.13K

+23936.00%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

92.59K

+10262.00%

Mr. Ori Gutwerg

Senior Vice President - Generics

84.02K

-5873.00%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

58.56K

-1622.00%

Mr. Patrick D. Walsh

Independent Chairman of the Board

58.41K

-11643.00%

Mr. Thomas Andrew (Thom) Rowland

Senior Vice President, Head of Established Brands

40.04K

-4975.00%

Mr. Thomas J. (Tom) Haughey, J.D.

Independent Director

36.52K

-19341.00%

Dr. Renee P. Tannenbaum, Pharm.D.

Independent Director

25.16K

-1800.00%

Mr. Matthew J. (Matt) Leonard

Independent Director

6.86K

-9465.00%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

411.22K

-56960.00%

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

310.13K

+23936.00%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

92.59K

+10262.00%

Mr. Ori Gutwerg

Senior Vice President - Generics

84.02K

-5873.00%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

58.56K

-1622.00%

Mr. Patrick D. Walsh

Independent Chairman of the Board

58.41K

-11643.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

Sales of Cortrophin Gel

101.85M

44.71%

Generic pharmaceutical products

94.38M

41.43%

Sales of ILUVIEN and YUTIQ

16.60M

7.29%

Brand

10.68M

4.69%

Royalty and other

4.31M

1.89%

La empresa aún no ha revelado los datos relevantes.

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Sales of Cortrophin Gel

101.85M

44.71%

Generic pharmaceutical products

94.38M

41.43%

Sales of ILUVIEN and YUTIQ

16.60M

7.29%

Brand

10.68M

4.69%

Royalty and other

4.31M

1.89%

Estadísticas de accionistas

Actualizado: dom., 1 de feb

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

10.43%

The Vanguard Group, Inc.

5.79%

Meridian Venture Partners

4.52%

State Street Investment Management (US)

3.17%

Esjay L.L.C,

2.82%

Otro

73.27%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

10.43%

The Vanguard Group, Inc.

5.79%

Meridian Venture Partners

4.52%

State Street Investment Management (US)

3.17%

Esjay L.L.C,

2.82%

Otro

73.27%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

39.61%

Investment Advisor/Hedge Fund

23.14%

Hedge Fund

19.38%

Individual Investor

7.44%

Research Firm

6.42%

Private Equity

4.52%

Corporation

2.84%

Pension Fund

1.66%

Bank and Trust

1.31%

Participación institucional



Actualizado: lun., 8 de dic

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

507

21.97M

100.49%

+14.84K

2025Q3

525

21.96M

103.27%

+407.79K

2025Q2

506

21.46M

110.44%

-446.10K

2025Q1

489

21.61M

106.49%

-1.37M

2024Q4

469

21.12M

108.93%

+156.97K

2024Q3

453

20.75M

88.54%

+3.60M

2024Q2

425

17.36M

85.19%

+1.07M

2024Q1

403

16.22M

82.13%

-1.01M

2023Q4

390

16.10M

82.95%

+39.70K

2023Q3

378

15.97M

79.12%

+734.26K

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

2.34M

10.43%

-29.49K

-1.24%

Sep 30, 2025

The Vanguard Group, Inc.

1.27M

5.67%

+116.00

+0.01%

Sep 30, 2025

Meridian Venture Partners

1.01M

4.52%

-150.00K

-12.88%

Aug 21, 2025

State Street Investment Management (US)

711.71K

3.17%

-4.41K

-0.62%

Sep 30, 2025

Esjay L.L.C,

632.62K

2.82%

-200.00K

-24.02%

Mar 14, 2025

Global Alpha Capital Management Ltd.

630.59K

2.81%

-231.50K

-26.85%

Sep 30, 2025

Citadel Advisors LLC

580.09K

2.58%

+10.46K

+1.84%

Sep 30, 2025

Dimensional Fund Advisors, L.P.

505.43K

2.25%

-48.47K

-8.75%

Sep 30, 2025

Geode Capital Management, L.L.C.

458.01K

2.04%

+30.47K

+7.13%

Sep 30, 2025

Deep Track Capital LP

450.00K

2%

-250.00K

-35.71%

Sep 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Invesco Pharmaceuticals ETF

2.63%

State Street SPDR S&P Pharmaceuticals ETF

2.42%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.95%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.63%

Innovator IBD Breakout Opportunities ETF

1.38%

Innovator IBD 50 Fund ETF

1.02%

Invesco Dorsey Wright Healthcare Momentum ETF

0.98%

Invesco S&P SmallCap Health Care ETF

0.96%

Janus Henderson Small/Mid Cap Growth Alpha ETF

0.92%

First Trust Small Cap Growth AlphaDEX Fund

0.67%

Invesco Pharmaceuticals ETF

Proporción2.63%

State Street SPDR S&P Pharmaceuticals ETF

Proporción2.42%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporción1.95%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proporción1.63%

Innovator IBD Breakout Opportunities ETF

Proporción1.38%

Innovator IBD 50 Fund ETF

Proporción1.02%

Invesco Dorsey Wright Healthcare Momentum ETF

Proporción0.98%

Invesco S&P SmallCap Health Care ETF

Proporción0.96%

Janus Henderson Small/Mid Cap Growth Alpha ETF

Proporción0.92%

First Trust Small Cap Growth AlphaDEX Fund

Proporción0.67%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos